Literature DB >> 9653958

Simultaneous high-performance liquid chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma.

A Le Liboux1, O Pasquier, G Montay.   

Abstract

Quinupristin-dalfopristin (30:70, w/w) is a new streptogramin, which has been developed for intravenous use. A specific and sensitive HPLC method was developed to measure simultaneously quinupristin (RP 57669) and dalfopristin (RP 54476) and their main metabolites in human plasma. The metabolites measured by this method were RP 69012 (glutathione-conjugated) and RPR 100391 (cysteine-conjugated) from quinupristin and RP 12536 (natural pristinamycin IIA), from dalfopristin. Solid-phase extraction with disposable cartridges was combined with reversed-phase HPLC and fluorimetric detection for RP 57669, RP 69012 and RPR 100391 and UV detection for RP 54476 and RP 12536. The method provided good recovery and low limits of quantitation (0.025 mg l(-1) for RP 57669, RP 54476 and RP 12536, and of 0.010 mg l(-1) for RP 69012 and RPR 100391). The validated range of concentrations of the method was: 0.025-5000 mg l(-1) for RP 57669, RP 54476 and RP 12536 and 0.010-0.750 mg l(-1) for RP 69012 and RPR 100391.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653958     DOI: 10.1016/s0378-4347(98)00005-x

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  5 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients.

Authors:  C A Johnson; C A Taylor; S W Zimmerman; W E Bridson; P Chevalier; O Pasquier; R I Baybutt
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Pharmacokinetics of quinupristin/ dalfopristin in patients with severe chronic renal insufficiency.

Authors:  P Chevalier; J Rey; O Pasquier; V Leclerc; J C Baguet; A Meyrier; N Harding; G Montay
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of quinupristin/dalfopristin.

Authors:  David T Bearden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Abyssomicins from the South China Sea deep-sea sediment Verrucosispora sp.: natural thioether Michael addition adducts as antitubercular prodrugs.

Authors:  Qian Wang; Fuhang Song; Xue Xiao; Pei Huang; Li Li; Aaron Monte; Wael M Abdel-Mageed; Jian Wang; Hui Guo; Wenni He; Feng Xie; Huanqin Dai; Miaomiao Liu; Caixia Chen; Hao Xu; Mei Liu; Andrew M Piggott; Xueting Liu; Robert J Capon; Lixin Zhang
Journal:  Angew Chem Int Ed Engl       Date:  2012-12-06       Impact factor: 15.336

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.